Compare · LLY vs PHVS
LLY vs PHVS
Side-by-side comparison of Eli Lilly and Company (LLY) and Pharvaris N.V. (PHVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PHVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.18T, about 570.6x PHVS ($2.06B).
- LLY has been more active in the news (19 items in the past 4 weeks vs 3 for PHVS).
- LLY has more recent analyst coverage (25 ratings vs 14 for PHVS).
- Company
- Eli Lilly and Company
- Pharvaris N.V.
- Price
- $1257.32+0.45%
- $27.72-6.41%
- Market cap
- $1.18T
- $2.06B
- 1M return
- -
- -27.04%
- 1Y return
- -
- +17.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 19
- 3
- Recent ratings
- 25
- 14
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Latest LLY
- Lilly confirms date and conference call for third-quarter 2026 financial results announcement
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
- Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
- SEC Form 3 filed by Eli Lilly and Company
- Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Latest PHVS
- SEC Form 4 filed by Pharvaris N.V.
- Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
- Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
- Director Monges Viviane exercised 11,969 shares at a strike of $8.05 and sold $395,524 worth of shares (11,969 units at $33.05) (SEC Form 4)
- President Lu Peng exercised 45,308 shares at a strike of $2.59, increasing direct ownership by 70% to 110,261 units (SEC Form 4)
- Director Schikan Johannes Gerardus Christiaan Petrus exercised 800 shares at a strike of $20.00 and sold $28,952 worth of shares (800 units at $36.19) (SEC Form 4)
- CFO / CLO Nassif David W. sold $218,801 worth of shares (6,000 units at $36.47) and gifted 500 shares, decreasing direct ownership by 5% to 113,800 units (SEC Form 4)
- President Lu Peng exercised 100,000 shares at a strike of $2.59 and sold $3,500,000 worth of shares (100,000 units at $35.00) (SEC Form 4)
- Director Schikan Johannes Gerardus Christiaan Petrus sold $7,000,000 worth of shares (200,000 units at $35.00), decreasing direct ownership by 63% to 115,167 units (SEC Form 4)
- SEC Form 144 filed by Pharvaris N.V.